New drug shows promise for lowering bad cholesterol without statins
NCT ID NCT05888103
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tested a drug called inclisiran in 207 Chinese adults with moderately high bad cholesterol (LDL-C) who were not taking other cholesterol medicines. Participants received either inclisiran or a placebo for 6 months, followed by 6 months where everyone got the drug. The main goal was to see how much inclisiran lowered LDL-C levels. The drug is designed to be taken long-term to control cholesterol, not to cure the condition.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PRIMARY HYPERCHOLESTEROLEMIA OR MIXED DYSLIPIDEMIA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Novartis Investigative Site
Jinzhou, Liaoning, 121001, China
-
Novartis Investigative Site
Linyi, Shandong, 276000, China
-
Novartis Investigative Site
Taiyuan, Shanxi, 030002, China
-
Novartis Investigative Site
Xian, Shanxi, 710061, China
-
Novartis Investigative Site
Chengdu, Sichuan, 610041, China
-
Novartis Investigative Site
Tianjin, Tianjin Municipality, 300121, China
-
Novartis Investigative Site
Hangzhou, Zhejiang, 310006, China
-
Novartis Investigative Site
Beijing, 100029, China
-
Novartis Investigative Site
Beijing, 100034, China
-
Novartis Investigative Site
Beijing, 100730, China
-
Novartis Investigative Site
Beijing, 101200, China
-
Novartis Investigative Site
Jinan, 250012, China
-
Novartis Investigative Site
Shanghai, 200025, China
-
Novartis Investigative Site
Shanghai, 200080, China
-
Novartis Investigative Site
Shanghai, 200120, China
-
Novartis Investigative Site
Tianjin, 300052, China
-
Novartis Investigative Site
Tianjin, 300140, China
-
Novartis Investigative Site
Fuzhou, Fujian, 350025, China
-
Novartis Investigative Site
Guangzhou, Guangdong, 510000, China
-
Novartis Investigative Site
Guangzhou, Guangdong, 510515, China
-
Novartis Investigative Site
Zhongshan, Guangdong, 528403, China
-
Novartis Investigative Site
Wuhan, Hubei, 430022, China
-
Novartis Investigative Site
Changsha, Hunan, 410003, China
-
Novartis Investigative Site
Changsha, Hunan, 410011, China
-
Novartis Investigative Site
Hohhot, Inner Mongolia, 010017, China
-
Novartis Investigative Site
Changzhou, Jiangsu, 213004, China
-
Novartis Investigative Site
Xuzhou, Jiangsu, 221003, China
-
Novartis Investigative Site
Nanchang, Jiangxi, 330009, China